

Cambridge University Press

978-0-521-62884-6 - Parkinson's Disease and Parkinsonism in the Elderly

Edited by Jolyon Meara and William C Koller

Index

[More information](#)

## Index

Note: page numbers in *italics* refer to figures and tables

- acetazolamide 89
- acetylcholinesterase inhibitors 42
- Achilles tendon stretch 206
- activities of daily living (ADL)
  - assessment 218, 220
  - scales 186
- affect–arousal 173
- age/aging 27
  - at diagnosis of PD 28–9
  - clinical heterogeneity of PD 27–30
  - essential tremor 82
  - neurodegenerative disease 111
  - prevalence of PD 112
  - risk of PD 114–15, 118
  - speech and language problems 227, 228
- agranulocytosis, fatal 65–6
- akinesia 1, 4, 5, 24, 25, 227
  - diagnosis 6
  - diagnostic criteria 7
  - dopamine agonists 149
  - progressive supranuclear palsy 9
  - swallowing mechanism 46
- alcohol, essential tremor 15, 85–6
- alprazolam 89
- Alzheimer's disease (AD) 7, 8, 9
  - age associated risk 111
  - concurrent 8
  - dementia with Lewy bodies 41
  - diagnostic errors 8
  - extrapyramidal signs 117–18
  - Lewy bodies 23
  - senile plaques 23
- amantadine 145–6, 157
  - essential tremor treatment 89–90
- amiodarone 72
- amisulpride 66
- amitriptyline 65, 154
- amphotericin B, DIP 73
- amplifiers 235
- anaesthesia 193
- anismus 158, 192
- ankle dorsiflexor stretch 207
  - reflex 208
- anti-emetics 71
- anticholinergic drugs 146
  - bladder dysfunction 10
  - constipation 10
  - gastric motility inhibition 158
  - hallucinations 157
  - neuroleptic-induced parkinsonism treatment 71
  - psychosis 42
  - urge incontinence 154, 155
- antidepressants 38, 224
  - impotence 156
- anxiety 223–4
  - assessment 200
  - dependency 168
  - disability determinant 173
- apomorphine 34, 45, 50–3, 135
  - administration 51, 52
  - challenge test 52, 187
  - injection site nodules 53
  - patient assessment 187
  - patient selection criteria 51–2
  - surgical patients 194
- apoptosis, selegiline inhibition 145
- articulation 229–30
  - impairment 227
- articulatory contacts 230
- aspiration 226, 236
  - laryngeal indicators 237
  - perioperative 193
- Assessment of Motor Processing and Skills 220
- assessment of patients 30, 32
- assessment tools, standardized 186
- assets 168
- Association of Chartered Physiotherapists
  - Interested in Neurology (ACPIN) 199

**241 Index**

- Association of Chartered Physiotherapists with a Special Interest in Elderly People (ACSIEP) 199
- atenolol 87
- Attendance Allowance 190
- attention deficit, selective 173
- autonomic dysfunction, severe 10
- autonomic failure 35
- autonomic function 43
- Babinski sign, vascular parkinsonism 13
- balance 47
  - evaluation 208–9
  - impaired 190
  - patient status assessment 200
  - physiotherapy 208–9
  - problems in elderly 33
- Balance Performance Monitor 209
- balance problems 34, 49
- Barthel Scale/Index 31, 186, 220
- basal ganglia 102, 103, 104
  - dopamine mediated gene regulation 34
- bathing 221
- benign essential tremor 83
- benserazide 135
- benzodiazepines 88–9
- benzquinamide 71
- benztropine 146
- Berg Scale 208
- beta adrenergic blockers 87–8
- bethahistine, neuroleptic substitute 70–1
- bethanechol 72
- Binswanger's disease 13, 101
- blood pressure 43
- Bobath approach 201
- body language, impaired 227
- body weight maintenance 191
- botulinum toxin injection 90
- bowel symptoms 45–6
- bradykinesia 235
  - medication strategy 149
- breathing
  - clavicular patterns 229
  - control 187
  - diaphragmatic 232
  - see also* respiration
- bromocriptine 137, 138–9
- bupropion 38
- cabergoline 137, 140, 154
- calcium channel blockers 72
- CAMCOG cognitive function assessment 31, 32
- Canadian Occupational Performance Measures (COPM) 218
- carbidopa 135, 136
  - controlled release 137
- carbonic anhydrase inhibitors 89
- care
  - quality 30
  - rehabilitation activity 166
- carers
  - asset value 168
  - communication for patient 236
  - dependency 168
  - distress 39
  - ill health 179
  - needs 128–9
    - palliative care 131
  - physiotherapy implications 204
  - psychological support 186
  - role in speech and language therapy 236
- catechol-*O*-methyltransferase (COMT)
  - central inhibition 142–3
  - inhibitors 142–4, 153
  - medication strategy 149
  - peripheral inhibition 142
- cephaloridine, DIP 73
- cerebral cortex, Lewy bodies 23
- cerebral multi-infarct states (CMIS) 98, 100–1, 104–5
- cerebrospinal fluid (CSF) shunt 14
- chin, tremor 85
- chlorpromazine 65
- chromosome 4q21–22 116–17
- cinnarizine 72
- cisapride 46
  - gastric motility 158
- clasp knife rigidity 5, 13
- clinical criteria, diagnostic 7
- clinical effectiveness evidence 129
- clinical guidelines 199
- clinical manifestations, essential tremor 82
- clinical trials 134–5
- clinics, specialist 126, 127, 130
- clonazepam 89
- clozapine 42, 65–6
  - hallucination control 157
  - tremor control 148
- co-beneldopa 135, 137
- co-careldopa 135
  - controlled release (CR) 136–7, 149
- co-danthramer 46
- cogentin 146
- cognitive function assessment 200
  - occupational therapists 224
- cognitive impairment 34, 39, 134, 199, 224
- cortical 41
- dementia risk 40
- depression 36–7

**242** Index

- cognitive impairment (*cont.*)
  - motor disability link 173
  - palliative care 49
  - subcortical 41
- cognitive therapy 224
- cogwheel rigidity 3, 15
  - lithium 72
- colon, myenteric plexus 158
- communication
  - assessment 200, 231
  - disorders 226, 227–30
  - environmental adaptations 234
  - nonverbal aspects 235–6
  - nursing care 187, 189
  - passive 236
  - sexuality 192–3
  - variability 235–6
- communicative impairment 173
- comorbidity, speech and language problems 227
- compensatory strategies, physiotherapy 204
- complementary therapies 179
- computed tomography (CT) 16, 17
- conductive education programmes 201, 222
- confusion, benzodiazepines 89
- constipation 10, 45–6, 158
  - nursing care 192
  - occupational therapy interventions 221
- continence advisor 45
- corollary discharges 198
- cortical loops 24–5
- corticobasal ganglionic degeneration (CBDG) 8
  - dopaminergic drugs 10
  - motor sign asymmetry 11
  - neuroimaging 17
- counselling 223
- Creutzfeldt–Jakob disease 8
- cytoplasmic inclusion bodies *see* Lewy bodies
  
- delayed auditory feedback 233
- delirium 134
  - drug-induced 42
- delusional ideas/delusions 36, 39, 42
- dementia 39–42, 173
  - causes 40
  - clinical characteristics 8–9
  - early 8–9
  - epidemiology 39–40
  - levodopa/PDI 149
  - with Lewy bodies 3, 8, 9, 40–1
  - management 42
  - neuropsychological features 41–2
  - normal pressure hydrocephalus 13, 14
  - nursing home admission 114
  - risk factors 40
- demographic change 122–3
  
- dentures 191
  - speech 229
- dependency 167–8
  - recognition 176
- deprenyl 144
- depression 35–9, 157–8, 223–4
  - assessment 200
  - associated features with PD 36–7
  - cognitive impairment 36–7
  - dementia risk 40
  - dependency 168
  - detecting 38
  - diagnostic criteria 35
  - disability determinant 173
  - dopamine 37
  - DSM-III criteria 36
  - epidemiology 35–6
  - medial prefrontal cortex 38
  - psychotic features 36
  - sleep disorders 154
  - treatment 38–9
- desmopressin 45, 155
- diagnosis
  - accuracy 6–7
  - atypical features 7–12
  - communication 177–8
  - milestones in PD 176, 177–9
  - progression to disability 177–9
- diagnostic accuracy 23, 111
- diagnostic criteria 30
  - predictive value 7
- diaphragmatic breathing 232
- diary keeping 151, 152
- diazepam
  - DIP 73
  - essential tremor treatment 89
- dietician 221
- diphasic dystonia/dyskinesia (D-I-D) dystonia 153
- disability
  - early 179, 180
  - impact of daily life 176
  - late stage 179, 181
  - variability 173–4
- disability organizations 176
  - see also* Parkinson's Disease Society
- disadvantage 166, 167
- disease aetiology theories 116
- disease progression, treatment strategy 149–50
- dizziness, treatment 70–1
- domperidone 33, 135
  - blood pressure 44
  - levodopa absorption 136
  - nausea control 136
  - neuroleptic substitute 70–1
  - surgical patients 194

Cambridge University Press

978-0-521-62884-6 - Parkinson's Disease and Parkinsonism in the Elderly

Edited by Jolyon Meara and William C Koller

Index

[More information](#)**243 Index**

- donazepil 42
- dopamine
  - deficiency 1, 23, 198
  - depression 37
  - loss 25
  - storage inhibitors 71–2
  - striatal depletion 69
  - striatal levels with COMT inhibitors 142–3
  - transport inhibitors 71–2
- dopamine agonists 137–8, 153
  - akinesia 149
  - orthostatic hypotension 44
  - psychosis 42
  - side effects 138
  - see also* apomorphine
- dopamine-mediated gene regulation, basal ganglia 34
- dopaminergic drugs 10–11
  - adverse reactions in PD 65
- dorsiflexion, active 207
- dorsiflexor stretch, reflex 208
- dosette 187
- dreams, vivid 47, 154
- dressing 220–1
- drinking 221
- driving ability 190, 222–3
- Driving Assessment Centres 223
- drooling *see* sialorrhoea
- drug therapy 134–5
  - cost/cost benefits 129
  - medication strategies 148–51, 152, 153–8
  - surgical patients 194
  - see also individual drugs*
- drug-induced parkinsonism (DIP) 2, 49, 64, 72–3, 117
  - calcium channel blockers 72
  - dopamine storage/transport inhibitors 71–2
  - gender 69
  - genetic influence 69
  - metabolic defect 69
  - neuroleptic-induced 65–71
  - PD distinction 68
  - subclinical PD 69–70
- dry mouth 191
- dyskinesia 47, 153
  - peak dose 150–1
  - sleep disturbance 154
- dysphagia 226, 236–7
  - see also* swallowing difficulties
- dysthymic disorder 35
- dystonia
  - anismus 158
  - off period 34
  - physiotherapy 209–10
  - wearing off 151, 153
- Easy Keys 235
- eating 221
  - aids 237
  - difficulties 191, 236–7
  - posture 237
  - see also* nutrition
- Edinburgh Masker 235
- educational programmes 126
- Eldepryl™ 144
- elderly patients, assessment of PD 30–2
- electroconvulsive therapy (ECT) 33, 38
  - neuroleptic-induced parkinsonism treatment 71
- emotionalism 35
- end of dose
  - deterioration 32–3
  - motor fluctuations 34, 150–1
- entacapone 142, 144
- environment 166
  - modification 167
  - safe 221
- environmental adaptations, communication 234
- environmental risk factors for PD 115
- epidemiology of parkinsonism 117–18
  - evaluation of studies 112
- epidemiology of PD 111–12
  - risk factors 114–17
- equilibrium apraxia 106
- equipment
  - feeding aids 237
  - provision 222
- erectile dysfunction 155, 192
- essential tremor (ET) 3, 14–15
  - age 82
  - alcohol 15, 85–6
  - beta adrenergic blockers 87–8
  - clinical manifestations 82–5
  - clinical variants 84–5
  - differential diagnosis 84
  - disability 83–4
  - epidemiology 80
  - factors influencing 82–3
  - genetics 80–1
  - prevalence 80, 81
  - treatment 85–91
  - tremor progression 82
- etat crible 13
- ethics, life sustaining measures 182
- exercise 189
  - early PD 202–3
  - mortality 212
  - physiotherapy 201
  - stretching 206
- exercise programme 178
  - speech and language therapy 231–2

**244** Index

- exercise tolerance 210  
 assessment 200
- external cues 108
- externally cued movements 106
- extrapyramidal reactions, piperazine derivatives 72
- extrapyramidal signs 117–18
- extrapyramidal syndromes, neuroleptic-induced 70
- eye of the tiger sign 17
- facial expression 235  
 loss 227
- faecal impaction 46
- falls 9–10, 34, 47, 190  
 benzodiazepines 89  
 late stage PD 179  
 management 209  
 multisystem degeneration parkinsonism 49  
 orthostatic hypotension 43  
 physiotherapy 208  
 prevention 172
- familial parkinsonism, autosomal dominant 111
- family history, risk factor 116
- features, atypical 7–12
- feeding *see* eating; meals; nutrition
- financing of health care 123
- Flewitt–Handford approach 201
- fludrocortisone 44, 156
- fluid intake 155, 156
- flunarizine 72
- 5-fluorouracil, DIP 73
- fluoxetine 38  
 DIP 73
- flurbiprofen 44
- focal infarction, single 13
- foot care 189, 208
- fractures, late stage PD 179
- free radical theory of cell death in PD 116
- freezing 9, 153–4  
 episodes 6, 47
- frontal fields 102
- functional disability, symptomatic therapy 148–9
- Functional Independence Measure 220
- Functional Limitations Profile 200
- funding systems 129
- gait 6, 9–10  
 deterioration 47  
 disturbance 206–7  
 freezing 9  
 problems 33, 34  
 re-education 207–8  
 senile 15–16
- gait apraxia 3, 14, 98  
 syndrome 98–100
- gait disorders  
 classification 101–2  
 normal pressure hydrocephalus 13–14  
 severe isolated 9  
 treatment 107  
 vascular disease 50  
 vascular parkinsonism 100–1  
*see also* vascular higher-level gait disorders
- gait ignition 102–4  
 impairment 105
- gastric motility 158
- gastrocolic reflex loss 46
- gegenhalten 5, 13
- general practitioner (GP) 123
- genetic anticipation, essential tremor 81
- genetic risk of PD 116–17, 118
- Geriatric Depression Scale (GDS-15) 32, 35
- ‘Get up and Go’ test 208
- globus pallidus 24, 25, 26  
 eye of the tiger sign 17
- glottal area tremor 210
- glycopyrrolate 155
- goal setting, joint 201
- grooming 220–1
- group programmes 204
- group therapy 222, 223  
 facial expression awareness 235  
 prosody 232, 233–4
- Hallervorden–Spatz disease 12, 17
- hallucinations 9, 36, 39, 47  
 drug-induced 157  
 levodopa/carbidopa CR 137  
 nursing home admission 114, 134
- hallucinoses 42  
 impaired vision/hearing 190  
 levodopa-induced 34
- haloperidol 65
- hand, essential tremor 82, 83
- handwriting 189  
 skills 223  
*see also* writing tremor
- head  
 control 235  
 essential tremor 82, 84, 87  
 injury risk factor 116  
 tremor 11
- health promotion 172
- Health Status Questionnaire 12 (HSQ-12) 32
- healthcare delivery 123
- healthcare needs 122, 171
- healthcare professionals  
 patient relationships 177  
 roles 174–5
- hearing 190

**245 Index**

- heel strike 207
- hemiballism 26
- hemiparkinsonism 37
- hemiparkinsonism hemiatrophy 11
- higher-level gait disorders 101–2, 108
  - see also* vascular higher-level gait disorders
- HLA B44 69
- hospital admission, nursing care 193–4
- Huntington's disease 12
  - patient needs 171
- hydrocephalus, normal pressure 8, 13–14
  - levodopa 10–11
  - neuroimaging 17
- hydrotherapy 205
- hyperkinesia, tetrabenazine therapy 71
- hyperreflexia, vascular parkinsonism 13
- hypnotic drugs 47–8, 154
- hypotension, orthostatic 43–4
- hydrocephalus, normal pressure 9
  
- ignition apraxia 105–6, 108
- immobility 47
- impotence 155, 192
- incidence of PD 111, 113
- inclusion bodies *see* Lewy bodies
- incontinence *see* urinary incontinence
- independence
  - medical management quality 172
  - PILS scheme 167–8, 170
- information
  - access to 176
  - availability 176–7
  - inaccurate 177
  - leaflets 176–7, 179, 189, 203
  - misconstrued 177
  - nurse provision 189
  - provision to patients 172
- institutional care 113–14, 134
- interventions
  - effectiveness 169–70
  - multidisciplinary 169
  - palliative 166
  - participation 169
  - physiotherapy 198
  - relevance 165
- intubation 193
  
- kinaesthetic information 198–9
  
- lactulose 46
- language
  - impairments 226–7
    - see also* speech and language problems; speech and language therapy
  - laryngeal muscle relaxation 233
- laxatives 46, 192
- lead-pipe rigidity 5, 13
- leaflets, information 176–7, 179, 189, 203
- leg cramps 154
- levodopa 10–11, 135–7
  - bioavailability 135–6
  - controlled release 135, 136–7, 149, 153
  - dementia management 42
  - dosage level 33, 136
  - formulations 33, 34
  - long-term therapy 134
  - metabolism 135
  - multisystem degeneration parkinsonism 49
  - orthostatic hypotension 44
  - peripheral decarboxylase inhibitor combination 135–6, 149, 153
  - side effects 33, 136
  - sustained release 154
  - terminal care 49
  - L-tryptophan addition 37
  - vascular parkinsonism 13
- Lewy bodies 1, 3, 23
  - Alzheimer's disease 23
  - brainstem 41
  - cortical 41
  - dementia 40–1
    - motor neurone disease 23
  - myenteric plexus of colon 158
    - see also* dementia, with Lewy bodies
- life event risk factors for PD 115, 116
- life sustaining measures, ethics 182
- lifestyle
  - PILS scheme 167, 168, 169, 170
  - risk factors for PD 115, 116
- Lightwriter 235
- limb oedema 211
- lithium 72–3
- long-term care 113–14
  
- Machado–Joseph disease 12
- Madopar™ 135
- magnetic resonance imaging (MRI) 16, 17
- masker, voice activated 235
- meals 221
- medial prefrontal cortex, depression 38
- medication
  - nursing care 187
    - strategies 148–51, 152, 153–8
  - meperidine, DIP 73
  - metoclopramide 136
  - methazolamide 89
  - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine *see* MPTP
  - alpha-methyl dopa 71–2
  - metoclopramide 67

Cambridge University Press

978-0-521-62884-6 - Parkinson's Disease and Parkinsonism in the Elderly

Edited by Jolyon Meara and William C Koller

Index

[More information](#)**246** Index

- metoprolol 87
- micturition
  - urgency 221
  - see also* nocturia; urinary incontinence
- midodrine 156–7
- mineralocorticoids 156
- Mini-Mental State Examination (MMSE) 31, 32, 200
- misdiagnosis of PD 117, 118
- mixed gait apraxia 106–7
- mobility 189–90, 222
  - deterioration 190
  - fluctuation 190
  - medical management quality 172
  - nursing care 189–90
  - visual cues 207–8
- monoamine oxidase-B inhibitors 144–5, 146–7
- mood
  - disorders 200
  - disturbances 37, 173
- mortality
  - exercise 212
  - from PD 111, 113
- motor blocks 6
- motor disability 37
  - cognitive impairment link 173
  - rehabilitation 33
- motor disorder, pathophysiology 198–9
- motor fluctuations 33–4
  - medication strategy 149–51, 152, 153–4
- motor neurone disease
  - age associated risk 111
  - Lewy bodies 23
  - patient needs 171
- motor programming failure 104
- motor signs
  - asymmetry 11
  - drug resistant 33
- motor syndromes 32–5
- motor tricks 153–4
- movement
  - internal sense 198
  - patient status assessment 200
  - practice 207
  - rotational components 205–6
- movement disorders
  - clinics 126, 127
  - social isolation 203
- MPTP 146–7
- multi-infarct disease 13
- multidisciplinary team 123, 126
  - goals 179
  - physiotherapist liaison 204
- multiple pathologies 171
- multiple sclerosis, patient needs 171–2
- multiple system atrophy (MSA) 7, 9, 10
  - autonomic function 43
  - epidemiology 117
  - levodopa response 10
  - parkinsonism 49, 50
  - rehabilitation 180, 182
  - striato nigral variant 50
- multisystem degenerative diseases, epidemiology 117
- multisystem neurodegenerative disease, parkinsonism 2–3
- muscle
  - changes in immobilized 206
  - flexor 206
  - strengthening 207
  - stretch 206
  - tone 200
- nadolol 87
- natural history of PD 111
- nausea treatment 70–1
- needs, perceived 176
- neurofibrillary tangles 41
- neuroimaging 16–18
- neuroleptic agents
  - atypical 66
  - DIP 65–7
- neuroleptic-induced parkinsonism 64–5, 65–71
  - agents 65–7
  - clinical features 67–8
  - duration 68
  - incidence 69
  - pathogenesis 69–70
  - susceptibility 69
  - treatment 70–1
- neuropathology
  - coexisting with PD 23
  - PD 22–3
- neurophysiological tests 16–18
- neurophysiology of PD 24–6
- neurosurgery 34–5
  - cost of procedures 129
  - see also* surgery
- neutropenia, neuroleptic-induced 66
- nightmares 154
- nigrostriatal tract 23, 25, 26
- nimodipine 72
- nocturia 154, 155
- nurse, specialist PD 126, 127, 174–5, 195
  - inpatient management guidelines 194
- nurses
  - community 175
  - psychological support 186
- nursing
  - assessment 186–7

Cambridge University Press

978-0-521-62884-6 - Parkinson's Disease and Parkinsonism in the Elderly

Edited by Jolyon Meara and William C Koller

Index

[More information](#)**247**      **Index**

- plan 188
- service purchasing 195
- team 185
- nursing care 185–6
  - communication 187, 189
  - components 187, 188, 189–95
  - continuity 185
  - elimination 191–2
  - hospital admission 193–4
  - information provision 189
  - medication 187
  - mobility 189–90
  - nutrition 191
  - palliative care 195
  - planning 185–6
  - sexuality 192–3
- nursing home residents 114, 134
- nutrition
  - nursing care 191
  - problems in late stage PD 179
  - see also* eating; meals
- occupational therapy 126, 127, 217
  - aims 217, 218
  - assessment 218, 220
  - dysphagia 237
  - evidence for effectiveness 224
  - frame of reference 218, 219
  - interventions 220–4
  - model of practice 218, 219
- off period
  - disability 35
  - dystonia 34
- olanzapine 42, 66
- on–off mood swings 37
- ondansetron 71
- oral hygiene 191
- Orem's Model of nursing care 187
- oro-motor assessment 237
- orthostatic hypotension 211
- oxybutynin 45
- palilalia 230
- palliative care 48–9, 130–1, 166
  - nursing care 195
  - physiotherapy 204
- parkinsonism 1
  - autosomal dominant 12
  - diagnosis 4, 5
  - drug-induced 12, 38
  - lower body 9, 13
  - multisystem neurodegenerative disease 2–3
  - post-encephalitic 12
  - pyramidal tract signs 11
  - rest tremor 6
  - unilateral acute onset 11
  - vascular 2, 13
    - levodopa 10–11
  - see also* drug-induced parkinsonism (DIP)
- Parkinson's disease (PD) 1–2
  - age at diagnosis 28–9
  - basal ganglia disordered cueing 104
  - clinical expression 28
  - clinical signs 4–7
  - coexisting neuropathology 23
  - concurrent Alzheimer's disease 8
  - conditions mimicking 12–16
    - with dementia 40
  - DIP distinction 68
  - heterogeneity 29
  - late onset 2, 29–30, 33
  - late stage 2, 28
  - neuropathology 22–3
  - neurophysiology 24–6
  - rapidly progressing 29
  - subclinical 69–70
  - subtypes 28–9
  - tremor dominant 7
- Parkinson's Disease Society 176, 193, 212
  - physiotherapy assessment 200
  - scale 200
  - Speech and Language Therapy checklist 231
- paroxetine 38
  - DIP 73
- participation 169
- pathology of PD 111
- patients
  - health care professionals relationships 177
  - psychological support 186
- PDQ-39 32, 200
- PDQL 32, 200
- percutaneous endoscopic gastrostomy (PEG)
  - feeding 182
- pergolide 45, 137, 139–40
- peripheral decarboxylase inhibitor (PDI) 135–6
- permissive exposure, latent period 116
- perphenazine 65
- pesticide use, risk factor 116
- pharynx, dysphagia 236
- phenelzine 73
- phenobarbital 89
- phenothiazines 66
  - fluorinated 65
- phonation 229
- phonemes, elision 230
- physical deficit combination with psychological deficit 173
- physical therapy 126
- physiotherapy 34, 126, 127, 166, 178
  - assessment 199–201



**248** Index

- physiotherapy (*cont.*)
- balance 208–9
  - breathing control 187
  - clinical guidelines 199
  - compensatory strategies 204, 207–8
  - disease progression 203–4
  - domiciliary 204–5
  - dystonia 209–10
  - early PD 202–3
  - environment 204–5
  - evidence base 211–12
  - exercise tolerance 210
  - falls 208
  - gait disturbance 206–7
  - hospital 205
  - intervention 198
  - late stage PD 204
  - management cycle 202
  - movement component treatment 205–11
    - range 206
      - rotational 205–6
    - muscle shortening 206
    - muscle strengthening 207
  - occupational therapy interventions 222
  - palliative care 204
  - respiratory function 210–11
  - review 202
  - tongue mobility 237
  - treatment approaches 200–4
  - walking aids 209
- PILS scheme 167–8
- evidence for intervention effectiveness 169–70
- pindolol 87
- piperazine
- derivatives 72
  - neuroleptic-induced parkinsonism 65
- pneumonia, aspiration 226, 236
- podiatry 189, 208
- positron emission tomography (PET) 17–18
- postural hypotension 156–7
- multiple system atrophy 182
- postural instability 6, 9–10
- postural reflexes
- absent 6
  - impaired 47
- posture
- advice 206
  - altered 235
  - assessment 237
  - feeding 237
  - patient status assessment 200
- pramipexole 137, 140–1
- pre-dementia 41
- premotor area (PMA) 102, 103–4
- pressure sores 190
- late stage PD 179
- prevalence of PD 111, 112–13
- prevention, PILS scheme 167, 170
- primary health care teams 195
- primary motor cortex (M1) 102, 103, 104
- primidone, essential tremor treatment 88
- private sector 176
- procaine 73
- prochlorperazine 136
- progression of disease 171–2
- progressive neurological disorders, needs 171–2
- progressive supranuclear palsy (PSP) 7, 8, 9
- epidemiology 117
  - levodopa response 10
  - neuroimaging 17
  - parkinsonism 49–50
  - rehabilitation 180
- PROPATH programme 231–2
- propiverin 155
- propranolol 71
- essential tremor treatment 87, 88
- proprioceptive neuromuscular facilitation 235
- prosodic cue perception 173
- prosodic therapy 232, 233–4
- prosody 230
- psychiatric disorders 173
- psychiatric disturbance, bromocriptine 139
- psychological deficit combination with physical deficit 173
- psychosis 42–3
- drug-induced 42
- putamen, cortical input 25
- pyridostigmine 72
- pyridoxine 71
- quality of care 30
- quality of life
- essential tremor 83
  - health related measures 32, 130
- quetiapine 66
- Reed and Sanderson model 218, 219
- referral, progressive paradigm 223
- rehabilitation 165
- apomorphine 52
  - assets 168
  - complexity 168–9
  - concepts 165–6
  - degenerative parkinsonian syndromes 180, 182
  - disadvantage 166, 167
  - effectiveness 169–70
  - goals 166
  - implementation 166–9
  - intensive inpatient 176
  - motor disability 33
  - multisystem degeneration parkinsonism 50
  - needs specific to PD/parkinsonism 172–4

**249 Index**

- nursing assessment 186–7
- resources 174–6
- service matching to needs 170–6
- speech and language therapy exercise programme 231–2
- strategies 176–9, 180–1
- structured process 169
- swallowing 236
- virtual reality images 104–5
- writing 223
- relaxation
  - therapy 223
  - total body 232
- REM behaviour disorder 48
- reserpine 71
- resources, rehabilitation 174–6
- respiration
  - associated impairments 229
  - reduced control 227
  - related symptoms and speech and language therapy 232
- respiratory function
  - assessment 200
  - physiotherapy 210–11
- respiratory muscle training 211–12
- respiratory status assessment 237
- respiratory support, speech 211
- rest tremor 7
  - absence 11–12
  - vascular parkinsonism 13
- rigidity 1, 4–5, 24
  - diagnostic criteria 7
  - essential tremor 15
  - facial expression 235
  - lithium 72
  - medication strategy 149
  - swallowing mechanism 46
  - vascular parkinsonism 13
  - see also* gegenhalten
- risk factors for PD 114–17
- risperidone 66
- ropinirole 137, 141
- seborrhoea 155
- secondary care 126
- selective attention 173
- selective serotonin reuptake inhibitors (SSRIs) 38, 39, 157, 158
  - DIP 73
  - impotence 156
  - serotonin syndrome 145
- selegiline 38, 144–5, 148, 154, 157
  - neuroprotection 146–7
  - orthostatic hypotension 44
  - psychosis 42
  - speech and language problems 227
- self-efficacy, subjective sense 172, 178–9
- self-funding treatment 129
- senile plaques 41
  - Alzheimer's disease 23
- serotonin 37, 38
  - precursors 37
  - syndrome 145
- sertindole 66
- sertraline 38, 158
- service organization/provision 123, 124–5, 126
  - economic appraisal 129
  - quality assessment 129–30
  - utilization 128
- services
  - access to 176
  - diagnosis specific 170–4
  - matching to needs 170–6
  - requirements in progressive neurological disorders 172
- sexual desire 192
- sexual dysfunction 48, 155–6
- sexuality, nursing care 192–3
- Short-Form 36 (SF-36) 32, 130
- sialorrhoea 42, 46, 146, 155, 191, 226
- Sinemet™ 135
- sitting exercises 189
- skin care 191
- sleep
  - abnormalities 154
  - disturbance/fragmentation 47–8
- smoking 116
- social isolation 203, 223
- social needs 122, 171
- social networks 126, 128
- social resources, PILS scheme 167, 168, 170
- social support 36, 126, 128
- soft tissue length/extensibility 200
- sotalol 87
- Sound Level Meter 234
- spasticity 5
- speech
  - abnormal rate treatment 232–3
  - articulation 229–30
  - coordination 229
  - difficulties 46
  - disorders in progressive supranuclear palsy 50
  - impairments 226–7
  - intonation improvement 233
  - rate 230
  - respiratory support 211
  - self monitoring 233
  - visual feedback 233
  - volume 234–5
    - loss 227, 229
- speech and language problems
  - age 227, 228

**250** Index

- speech and language problems (*cont.*)  
 comorbidity 227
- speech and language therapist 187
- speech and language therapy 126, 127, 210, 226  
 carer role 236  
 exercise programme 231–2  
 intensive 232  
 respiratory related symptom treatment 232  
 treatment 231–4
- Speechviewer (IBM) 234–5
- spino bulbar muscular atrophy, X-linked 81
- standing exercises 189
- state disability allowances 190
- state funding 129
- stress 36, 223
- stress incontinence 192
- substantia nigra  
 cell loss 22  
 gliosis 22  
 nigrostriatal tract 23  
 pars compacta 22, 23, 25  
 cell degeneration 1  
 pars reticulata 22, 24, 25
- subthalamic nucleus 25–6, 26
- supplementary motor area (SMA) 102, 103  
 infarction 104
- supraglottal area tremor 210
- surgery 193  
 drug treatment 194  
*see also* neurosurgery
- swallowing difficulties 226–7, 228, 236–7  
 disease progression 46  
 dopaminergic therapy 155  
 drooling 155  
 impairment in progressive supranuclear palsy 50  
 late stage PD 179  
 multiple system atrophy 182  
 rehabilitation techniques 236
- syllables, elision 230
- symptom diary 151, 152
- syncope 43, 44
- alpha-synuclein 117
- tablet containers 187
- tacrine 42
- tardive dyskinesia 70, 71
- teamwork 174–6
- telephone amplifiers 235
- terminal illness 130–1  
*see also* palliative care
- tetrabenazine 71
- thalamic inhibition 24–5
- thalamic stimulation  
 essential tremor treatment 91  
 refractory tremor 148
- thalamotomy  
 essential tremor treatment 90  
 refractory tremor 148
- thioridazine 65
- thioxanthenes 66
- timolol 87
- tocopherol 147
- toileting 221
- tolcapone 34, 142, 143
- tolterodine 155
- tongue  
 essential tremor 87  
 mobility 237  
 tremor 85, 236
- torsion dystonia, autosomal dominant idiopathic 81
- training provision to patients 172
- transcutaneous nerve stimulation (TENS) 211
- treatment  
 individualized plan 201  
 nursing care regimes 187  
 problem solving approach 200–1
- tremor 1, 24  
 diagnostic criteria 7  
 drug treatment 148  
 essential 7, 11–12  
 glottal area 210  
 head 11  
 lithium 72  
 medically undiagnosed 117  
 medication strategy 148, 149  
 pill-rolling 6  
 postural 72  
 rest 5–6  
 supraglottal area 210  
 task-specific 84, 85  
 tongue 236  
 writing 84  
*see also* essential tremor (ET); rest tremor
- tricyclic antidepressants 38, 154, 157
- trihexylphenidyl 146
- trunk mobility exercises 210
- trunk mobilization techniques 207
- L-tryptophan 37
- Unified Parkinson's Disease Rating Scale (UPDRS)  
 30–1, 186  
 score 211
- urethral sphincter electromyography 10
- urge incontinence 154–5, 191–2
- urinary bladder symptoms 45
- urinary incontinence 10, 154–5  
 multiple system atrophy 180  
 normal pressure hydrocephalus 13, 14  
 nursing care 191–2
- urodynamic studies 10

Cambridge University Press

978-0-521-62884-6 - Parkinson's Disease and Parkinsonism in the Elderly

Edited by Jolyon Meara and William C Koller

Index

[More information](#)**251**      **Index**

- vaginismus 192
- vascular higher-level gait disorders 98, 102, 104–5
  - classification 105–7, 108
  - disequilibrium 105
  - equilibrium apraxia 106
  - ignition apraxia 105–6
  - mixed gait apraxia 106–7
  - physiotherapy 107
  - treatment 107–8
- vascular parkinsonism 100–1
- ventilation during surgery 193
- videofluoroscopy 237
- videotapes 189, 203
- vincristine/adriamycin combination, DIP 73
- virtual reality images, rehabilitation 104–5
- vision 190
- visual cues, mobility 207–8
- visual feedback, speech 233
- visual impairment, progressive supranuclear palsy 50, 180
- vitamin C, protective effect for PD 116
- vitamin E *see* tocopherol
- vocal cords, abduction/adduction 210
- Vocalite 232
- voice
  - essential tremor 87
  - tremor 82, 83, 85
  - volume 227, 229, 234–5
- voluntary motor control loss 24
- voluntary organizations 176
- walking 189
  - aids 204, 209
  - confidence 206
  - elderly 15–16
- walking frames 209
- walking sticks 209
- washing 221
- wearing off
  - dystonia 151, 153
  - motor fluctuations 150–1
- Webster Scale 200
- welfare workers 176
- wheelchair 222
- Wilson's disease 12
- World Health Organization Classification of Impairments, Disabilities and Handicaps 166
- writing tremor
  - primary 84
  - see also* handwriting
- ziprasidone 66
- zolpidem 154
- zotepine 66